Silence Therapeutics plc has announced that the Company's name change from SR Pharma plc has been completed.
The new company name, Silence Therapeutics, and corporate identity have been put in place to reflect the Company’s core focus on RNAi, a therapeutic approach which seeks to ‘silence’ disease relevant genes.
Silence Therapeutics is developing a broad pipeline of RNAi therapeutics based on its proprietary AtuRNAi molecules and systemic delivery system, AtuPLEX.
Silence Therapeutics’ in-house RNAi therapeutic programmes, which are in late-stage pre-clinical development, are focused on systemic cancer indications such as gastro-intestinal and non-small lung cancer.
In addition, Silence Therapeutics has AtuRNAi molecules in clinical development via its collaborators Quark Biotech and its sublicensee Pfizer.
The Company is now trading under the ticker SLN on the AiM market.